OR WAIT null SECS
April 02, 2023
What can we take away from Pfifzer's acquisition of Seagen?
A further setback to the publication of the pharmaceutical legislative changes in Europe may mean time is running out for appropriate review before 2024 parliamentary elections.
March 02, 2023
Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.
February 02, 2023
Although some headway is being made into more gender-diverse executive levels in pharma, much more work is still needed.
This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.
January 02, 2023
Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”
The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.
December 02, 2022
Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.
mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.
November 02, 2022
Industry and the government must work closely to ensure the UK remains a competitor in the clinical research field.